News
BMS eyes another celmod filing in myeloma after phase 3 win
Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.
Home
FDA cuts testing requirements for biosimilars once again
The FDA has issued additional guidance that aims to make it easier for drugmakers to bring biosimilars of patent-expired biologic drugs to market.
R&D
Closed & Collaborative – January to February 2026
January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.
News
Roche's oral SERD flunks phase 3 breast cancer test
Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.
News
Servier snaps up cancer biotech Day One in $2.5bn deal
Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
